CAS NO: | 195615-84-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Blarcamesine hydrochloride is aSigma-1 Receptoragonist with anIC50of 860 nM. | ||||||||||||||||
IC50& Target | IC50: 860 nM (Sigma-1 Receptor)[1] | ||||||||||||||||
体内研究 (In Vivo) | The pre-administration of Blarcamesine leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg[1]. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1 mg/kg. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1 mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser9phosphorylation induced by the peptide at 0.3 and 1 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ25-35-induced increase in Aβ1-42content, with a significant effect at the highest dose tested[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 317.85 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C19H24ClNO | ||||||||||||||||
CAS 号 | 195615-84-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 100 mg/mL(314.61 mM;Need ultrasonic) DMSO : 25 mg/mL(78.65 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|